MILLENNIUM PARTNERS: Form 8.3 - Allergan plc
May 12 2020 - 10:15AM
UK Regulatory
TIDMIRSH TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Millennium International Management LP
Company dealt in Allergan plc
Class of relevant security to which IE00BY9D5467
the dealings being disclosed relate
(Note 2)
Date of dealing 11(th) May 2020
2. INTERESTS AND SHORT POSITIONS
1. Interests and short positions (following dealing) in the class ofrelevant
security dealt in(Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 0 0
(0.000%) (0.000%)
(2) Derivatives (other than options) - -
(3) Options and agreements to purchase/sell - -
Total 0 0
(0.000%) (0.000%)
b. Interests and short positionsin relevant securitiesof the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
3. DEALINGS (Note 4)
1. Purchases and sales
Price per unit (Note 5)
Purchase/sale Number of relevant securities (USD)
Sale 130,165 193.01
Sale 965,039 193.01
Sale 415,101 193.01
Sale 276,702 193.01
Sale 645,796 193.01
Sale 5,979 193.01
Purchase 133 193.01
Purchase 14,619 193.01
Sale 1,688,153 193.01
Purchase 2,580 193.01
Sale 8 193.01
Purchase 3,721,191 193.01
Sale 3,826,467 193.01
Sale 1,270,619 193.01
1. Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
b. Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this
should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 12(th) May 2020
Contact name Milos Naumovic
Telephone number +44 203 650 8203
If a connected EFM, name of offeree/offeror with which
connected
If a connected EFM, state nature of connection (Note 10)
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200512005523/en/
CONTACT:
Millennium Partners, L.P.
SOURCE: Millennium Partners, L.P.
Copyright Business Wire 2020
(END) Dow Jones Newswires
May 12, 2020 10:15 ET (14:15 GMT)
Allergan (LSE:0Y7T)
Historical Stock Chart
From Dec 2024 to Jan 2025
Allergan (LSE:0Y7T)
Historical Stock Chart
From Jan 2024 to Jan 2025